



Safety and Side Effects in SARS-CoV-2 Vaccine

Guest Editors:

Dr. Ying-Fei Yang

Department of Bioenvironmental Systems Engineering, National Taiwan University, Taipei 10617, Taiwan

Dr. Sher Singh

Department of Life Science, School of Life Science, College of Science, National Taiwan Normal University, Taipei 11677, Taiwan

Deadline for manuscript submissions:

31 May 2025

Message from the Guest Editors

COVID-19 vaccines are important in the global battle against the SARS-CoV-2 pandemic. The swift development and distribution of COVID-19 vaccines, including mRNA (Pfizer-BioNTech, Moderna), viral vector (AstraZeneca, Johnson & Johnson, Sputnik V), and protein subunit (Novavax) vaccines, or inactivated virus (Sinovac, Sinopharm) vaccines, have been unprecedented. This Special Issue invites research papers and reviews that enhance current understanding of these vaccines' safety and side effects, focusing on special populations (e.g., the elderly and children, pregnant and lactating women, and immunocompromised individuals) and rare adverse events. Understanding these aspects is critical for healthcare providers and policymakers to improve vaccine confidence and optimize public health strategies. We also welcome articles on vaccine safety monitoring systems, e.g., the vaccine adverse event reporting system (VAERS) and the vaccine safety datalink (VSD). We look forward to receiving your research articles, including reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com